Starpharma Holdings Limited (SPHRF)

USD 0.06

(7.53%)

Market Cap (In USD)

25.09 Million

Revenue (In USD)

8.28 Million

Net Income (In USD)

-8.16 Million

Avg. Volume

1780.00

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.0558-0.12
PE
-3.0
EPS
-0.02
Beta Value
0.762
ISIN
AU000000SPL0
CUSIP
-
CIK
-
Shares
418225000.0
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Ms. Cheryl Maley B.Sc., M.B.A.
Employee Count
-
Website
https://starpharma.com
Ipo Date
2007-04-30
Details
Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.